Dr. Saad Usmani of the Levine Cancer Institute in Charlotte, North Carolina, gives his perspective on the treatment options for newly diagnosed as well as relapsed/refractory multiple myeloma patients, as discussed this weekend at the American Society of Hematology (ASH) annual conference in Orlando, Florida.
Author: Editor
Dr. Meletios Dimopoulus provides an update on the Eloquent-2 Trial: A Phase 3 Randomized, Open-Label Study of elotuzumab in Combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma. Dr. Meletios Dimopoulos National and Kapodistrian University of Athens School of Medicine Athens, Greece Elotuzumab is an immunostimulatory monoclonal antibody (mAb) that recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein highly expressed by myeloma and natural killer cells. Elotuzumab has a dual mechanism of action, directly activating natural killer cells and initiating antibody-dependent cell-mediated cytotoxicity targeted against myeloma cells, with minimal effect on normal tissues. In the 2-year progression-free survival (PFS)…
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Toby Talbot, MB BS, of Royal Cornwall Hospitals NHS Trust, Truro, UK, reviews the advances in cancer immunotherapeutic approaches, highlighting the development of the anti-CTLA4 monoclonal antibody, ipilimumab, for the treatment of metastatic melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr. Saad Usmani reports on the clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis – a Matched Case Control Study Dr. Ashutosh Wechalekar National Amyloidosis Centre University College London London, United Kingdom Survival of patients with cardiac AL amyloidosis remains poor due to high mortality in the first 6-12 months. Rapidly effective regimes such as CyBorD are unable to overcome poor prognosis in very advanced AL amyloidosis (Venner et al and Palladini et al Leukemia 2014). The median survival of moderately advanced AL is ~60% at 2 years with CyBorD (Palladini et al Blood 2015). Last year, we reported a small series suggesting that oral…
Richard Henry, President Elect of the United Kingdom Oncology Nursing Society (UKONS), and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, discusses the overarching theme of patient safety and the subsidiary topic of haemato-oncology nursing at the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Tim Anstiss, MB, MEd, D.Occ.Med, MFSEM, of the Academy for Health Coaching, explains the concept of motivational interviewing as an approach for clinicians to communicate with patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr. Damian Green of Seattle Cancer Care Alliance presented at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discuses three new treatment options available for patients with multiple myeloma, and the role that clinical trials played in discovery of the new options.
Dr. Ryan Cassaday of Seattle Cancer Care Alliance presented a poster at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discusses how a treatment called hyperCVAD is making a difference for patients with ALL.
Myeloma UK provides information and support for individuals affected by multiple myeloma. At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager at Myeloma UK, Edinburgh, UK, discusses Myeloma UKs Myeloma Academy, which is an interactive learning platform designed to provide continuing professional development opportunities for multiple myeloma healthcare professionals in order to support optimal patient care. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Berman, MBBS, MRCGP, FRCP, of The Christie NHS Foundation Trust, Manchester, UK, discusses the recent progress, including the development of 5-HT3 and neurokinin-1 receptor antagonists as potential pharmacologic treatment options, in the management of chemotherapy-induced nausea and vomiting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr. Naughton recognizes the difference between risk of recurrence and likelihood of benefit from extended endocrine therapy, noting the two do not always correlate, as they can be based on separate biological mechanisms. A patient at high risk of recurrence does not inherently imply that patient will respond to a particular therapy.
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the ManVan initiative, which is the first dedicated mobile support service for men with prostate, testicular or penile cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Somatic Profiles – NGS Testing
MPN expert Dr. Rami S. Komrokji, Clinical Director of the Malignant Hematology Department at the Moffitt Cancer Center, shares his perspective on the future of research for myeloproliferative neoplasms, new medications and clinical trials. Dr. Komrokji explains how research, past and current, is pushing MPNs closer to becoming a chronic disease. He discusses both existing and new drug therapies and clarifies patient benefits when considering a clinical trial. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Patient Power Founder Andrew Schorr caught with patient #1 in the elotuzumab trial, Jay Carty, to get his thoughts on the approval and his perspective on the future of myeloma treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
As part of our Ask the Expert series, MPN expert Dr. Jamile Shammo of Rush University Medical Center responds to a Patient Power community members question, What do we know about ET and PV progression to myelofibrosis? Are there any ways progression can be slowed down? What research is being done in this area? Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
@OncEd Presents Dr. Barb Melosky – Best of Lung Cancer – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Winson Cheung – Best of Health Services / Survivorship – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Scott North – Best of Prostate – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Christian Kollmannsberger – Best of Non-Prostate – best of ASCO 2015 Vancouver
@OncEd Presents Dr. Stephen Chia – Best of Breast Cancer – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Michael Smylie – Best of Melanoma – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Howard Lim – Best of Non-Colorectal – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Sharlene Gill – Best of Colorectal – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Kerry Savage – Bet of Lymphoma – Best of ASCO 2015 Vancouver
@OncEd Presents Dr. Cheryl Ho – Best of Head and Neck – Best of ASCO 2015 Vancouver
@OncEd Presents Pancreatic Tumour Board – 2015
@OncEd Presents Dr. Allan Covens – BRCA Mutations in Ovarian Cancer – 2015
@OncEd Presents Dr. Scott Berry – First Line treatment of Unresectable Metastatic Colorectal Cancer – 2015
@OncEd Presents Dr. Natasha Leighl – Best of Lung Cancer – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Martina Trinkaus – Best of Hematology – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Eric Chen – Best of Head and Neck – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Kala Sridhar – Best of Non-Prostate – Best of ASCO 2015 Toronto
@OncEd Presents Dr. S̩bastien Hotte РBest of Prostate РBest of ASCO 2015 Toronto
@OncEd Presents Dr. Ron Burkes – Best of Colorectal – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Anthony Brade – Best of Radiation Oncology – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Yoo-Joung Ko – Best of Non-Colorectal – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Marcus Butler – Best of Melanoma – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Philippe Bedard – Best of Breast Cancer – Best of ASCO 2015 Toronto
@OncEd Presents Dr. Benoit Samson – Best of Survivorship – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Jamil Asselah – Best of Breast Cancer – Best of ASCO 2015 Montreal
@OncEd Presents Dr. F̩lix Couture РBest of Colorectal РBest of ASCO 2015 Montreal
@OncEd Presents Dr. John Storring – Best of Hematology – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Benoit Samson – Best of Lung Cancer – Best of ASCO 2015 Montreal
@OncEd Presents Dr. Fr̩d̩ric Lemay РBest of GI Cancers РBest of ASCO 2015 Montreal
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses a doctoral study that was designed to evaluate the lived experience of men who have survived at least five years after a diagnosis of prostate cancer received at or after the age of 65 years. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Joanne Upton, Skin Cancer Advanced Nurse Practitioner at The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK, discusses the development of a nurse-led, pre-treatment, telephone assessment service to address waiting times for patients receiving ipilimumab for metastatic melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager, Myeloma UK, Edinburgh, UK, discusses the role of nurses for improving the quality of life and survival of patients with multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
@OncEd Presents Dr.Fran̤ois Patenaude РBest of Renal Cancer РBest of ASCO 2015 Montreal